In general, tenofovir disoproxil and emtricitabine with both dolutegravir and raltegravir are well tolerated when taken as PEP.^{17,24,25,27,28,56,65}

If a patient reports intolerable or serious side-effects from a previous PEP course:

• an alternative PEP regimen should ideally be prescribed
• in emergency (out of hours) situations (unless previously reported side-effects were serious) the available PEP regimen starter pack should be prescribed with urgent specialist follow-up arranged to monitor the PEP regimen. 

Proximal renal tubular dysfunction (including Fanconi syndrome) has been reported among people with with HIV on tenofovir disoproxil-containing therapy,⁶⁶ but has not been reported among patients prescribed a 28-day PEP course.
Myopathy or severe rhabdomyolysis has been reported, albeit rarely, with use of dolutegravir and raltegravir.^67-70 It is advised that:

• patients on PEP should be monitored for symptoms
• caution should be taken among those with a past history of myopathy, or co-administration with medications such as statins,⁷¹ which may also cause myopathy
• creatine kinase (CK), renal function and urinary myoglobin should be checked in patients who report myalgia.